This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Top 10 Emerging Markets Stocks in 2010

Stocks in this article: ABV CEO RDY SINA CTSH TTM ZNH MPEL SVM BIDU

8. Dr. Reddy's Laboratories (RDY - Get Report) is an integrated pharmaceutical company focusing on global generics, pharmaceutical services, and active ingredients and proprietary products.

On a year-to-date basis, the company soared 52.5%, touching 52-week highs in December. In comparison, counterparts GlaxoSmithKline (GSK - Get Report), Teva Pharmaceutical Industries (TEVA - Get Report) and Pfizer (PFE - Get Report) declined 7.4%, 7.9% and 3.3%, respectively. Industry giant Novartis (NVS - Get Report) gained 8.6%.

The company recently signed a licensing, technology transfer, manufacturing and marketing agreement with R-Pharm of Russia, working on a profit-sharing model. During October, the company announced expansion of its products portfolio in the Russian and Ukraine markets through in-licensing deals with companies like Cipla and Vitabiotics. During early 2010, rumors that GSK was planning to acquire a 5% stake in Reddy's for almost $150 million-$160 million were disregarded as unlikely to happen. Furthermore, Dr. Reddy's also denied that it is seeking to sell its Indian formulations business to Pfizer.

During the first half of 2011, Dr. Reddy's is likely to close its deal with GlaxoSmithKline and complete the transfer of GSK's U.S. oral penicillin facility and product portfolio ownership rights. The transfer will likely add $40 million to the company's top line in 2011-2012.

The company is looking for partnerships in order to enter the Japanese generic drugs markets. Japan offers vast opportunities, as the government is keen to make health care more affordable.

Dr. Reddy's is forecasting sales of $1 billion in the U.S. by 2012-2013, up 42% from 2010 levels. The company aims to record $3 billion in revenue by 2013. Besides planning a single launch every year in the low competition/patent challenge segments, Dr. Reddy's has a pipeline of 12 first-to-file opportunities that provide six months exclusivity at launch. The market size of these products is valued at $9 billion.

4 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,678.70 +6.10 0.03%
S&P 500 2,057.09 +5.27 0.26%
NASDAQ 4,771.7630 +13.8840 0.29%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs